Switching to ozanimod as a strategy to adjust fingolimod-related lymphopenia
Author:
Funder
Ministero dell'Istruzione dell'Universita e della Ricerca
Publisher
Elsevier BV
Subject
Neurology (clinical),Neurology,General Medicine
Reference18 articles.
1. Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives;Bravo;Cells,2022
2. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial;Cohen;Lancet Neurol.,2019
3. Benefit–Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis;Comi;Drugs,2017
4. Severe fingolimod rebound syndrome after switching to cladribine treatment;Coss-Rovirosa;Mult. Scler. Relat. Disord.,2020
5. EMA, 2023. Gilenya : EPAR - Product Information [WWW Document]. First published: 30/03/2011 Last updated: 15/09/2023 URL https://www.ema.europa.eu/en/documents/product-information/gilenya-epar-product-information_en.pdf.
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3